GlassScriptPhysician profile
Seema Haq
NPI 1013066869
$10,982.98
in general payments reported to CMS, 2019-2025
54 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,041 · 2020: $578 · 2021: $1,185 · 2022: $1,801 · 2023: $1,828 · 2024: $1,794 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,369 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,369.26 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,128.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $937.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $847.96 | 2019-2023 | Farxiga |
| Amgen INC. | $757.43 | 2019-2025 | Evenity, Tepezza, Prolia |
| Mannkind Corporation | $697.09 | 2019-2025 | Afrezza |
| Radius Health, INC. | $640.81 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $633.56 | 2019-2025 | |
| Insulet Corporation | $555.23 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $525.68 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.83 | 2019-2025 | Jardiance |
| Beta Bionics, INC. | $298.24 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Dexcom, INC. | $285.11 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $223.23 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $163.67 | 2019-2022 | |
| Cequr Corporation | $161.43 | 2022-2025 | Cequr Simplicity |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.